27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Baker Brothers Advisors, a hedge fund run by Julian and Felix Baker, disclosed after Monday's market close it acquired 106,800 shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) for $7.28 per share.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
BioCryst Pharmaceuticals is a biotechnology company that develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. Its stock closed at $7.49 on Monday.
Shares of BioCryst were trading near the $8.00 level during Tuesday's pre-market session. The stock opened for trading at $7.61 and hit an intra-morning high of $7.68 before reversing direction. After 50 minutes of trading, shares of BioCryst were trading lower by 3.47 percent at $7.23.